2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

L-M cell

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

3

Inhibitory Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-155309
    LM-41

    		YAP Cancer
    LM-41 is a Flufenamic acid-derived TEAD inhibitor hat strongly reduce the expression of CTGF, Cyr61, Axl and NF2. LM-41 inhibits migration of human MDA-MB-231 breast cancer cells .
    LM-41
  • HY-156112
    LM2I

    		Ser/Thr Protease Cancer
    LM2I is a derivative of Spinosyn A (SPA). LM2I is argininosuccinate synthase (ASS1) enzyme activator, and tumor inhibitor that directly interact with ASS1. LM2I has significant antiproliferative activity in seven colorectal cancer cell-lines and xenograft tumors of colorectal cancer. LM2I inhibits colorectal cancer cell growth via the EGFR pathway .
    LM2I
  • HY-110155
    LM11A-31 dihydrochloride
    Maximum Cited Publications
    7 Publications Verification

    		 Neurotensin Receptor Neurological Disease
    LM11A-31 dihydrochloride, a non-peptide p75 NTR (neurotrophin receptor p75) modulator, is an orally active and potent proNGF (nerve growth factor) antagonist. LM11A-31 dihydrochloride is an amino acid derivative with high blood-brain barrier permeability and blocks p75-mediated cell death. LM11A-31 dihydrochloride reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progression .
    LM11A-31 dihydrochloride
  • HY-117088
    LM11A-31
    Maximum Cited Publications
    7 Publications Verification

    		 Neurokinin Receptor Neurological Disease
    LM11A-31, a non-peptide p75 NTR (neurotrophin receptor p75) modulator, is an orally active and potent proNGF (nerve growth factor) antagonist. LM11A-31 is an amino acid derivative with high blood-brain barrier permeability and blocks p75-mediated cell death. LM11A-31 reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progression .
    LM11A-31
  • HY-P991520
    LM-108

    		CCR Cancer
    LM-108 is an anti-CCR8 monoclonal antibody. LM-108 selectively depletes tumor-infiltrating targeting tumor-infiltrating regulatory T cells (Tregs). LM-108 can be used for the study of gastric cancer .
    LM-108
  • HY-171754
    LM-305

    		Antibody-Drug Conjugates (ADCs) Cancer
    LM-305 is an anti-G protein-coupled receptor class 5 member D (GPRC5D) antibody-drug conjugate (ADC). LM-305 consists of Anti-GPRC5D Antibody (HY-P991197) and VcMMAE (HY-15575). LM-305 exhibits potent cytotoxicity against multiple myeloma cells (NCI-H929 and MM.1R) with IC50 values ranging from 0.1 to 0.3 nM. LM-305 can be used in the study of GPRC5D-related relapsed and refractory multiple myeloma (RRMM) .
    LM-305
  • HY-13442C
    Eribulin (mesylate) (purity>99%, single impurity ≤ 0.15%)

    B1939 (mesylate) (purity>99%, single impurity ≤ 0.15%); E7389 (mesylate) (purity>99%, single impurity ≤ 0.15%); ER-086526 (mesylate) (purity>99%, single impurity ≤ 0.15%)

    		 Microtubule/Tubulin Apoptosis Cancer
    Eribulin mesylate (purity>99%, single impurity ≤ 0.15%) is an inhibitor for microtubule. Eribulin mesylate (purity>99%, single impurity ≤ 0.15%) inhibits the proliferation of cancer cell LM8 and Dunn, inhibits the cell migration of LM8, arrests the cell cycle at G2/M phase, and induces apoptosis in LM8. Eribulin mesylate (purity>99%, single impurity ≤ 0.15%) exhibits antitumor efficacy in mouse model .
    Eribulin (mesylate) (purity>99%, single impurity ≤ 0.15%)
  • HY-157975
    LM11

    		Glutaminase Cancer
    LM11 is an inhibitor of transglutaminase 2 (TG2) with an activity of killing glioblastoma cells by maintaining TG2 in a cytotoxic conformational state .
    LM11
  • HY-P99692
    Lenercept

    p55TNF-R:Ig; Ro 45-2081; TNFR55-IgG1

    		 TNF Receptor Inflammation/Immunology
    Lenercept (Ro 45-2081) is a recombinant fusion protein that consists of the soluble TNF-receptor (p55) linked to the Fc portion of human IgG1 .
    Lenercept
  • HY-164915
    5-InoAz

    		Bacterial Metabolic Disease
    5-InoAz is an inositol analogue used as a metabolic probe for labeling the mycobacterial cell envelope. 5-InoAz integrates into cell envelope glycolipids [phosphatidylinositol mannoside (PIM), PIM-anchored lipomannan (LM), and lipoarabinomannan (LAM)] .
    5-InoAz
  • HY-172394
    ZSNI-21

    		HDAC ADAMTS Cancer
    ZSNI-21 is a dual inhibitor of ADAM17 and HDAC2. ZSNI-21 effectively inhibits the proliferation of Bel-7402 cells and demonstrates significant anti-metastatic capabilities against HCC-LM3 cells. ZSNI-21 is promising for research of hepatocellular carcinoma (HCC) .
    ZSNI-21
  • HY-143402
    Topoisomerase I/II inhibitor 2

    		Topoisomerase Cancer
    Topoisomerase I/II inhibitor 2 (compound 1a) is a potent Topoisomerase inhibitor (IC50= 9.82 μM on Huh7 cells and 6.83 μM on LM9 cells). Topoisomerase I/II inhibitor 2 has dual inhibition on DNA topoisomerase I/II, also can obviously reduce the growth of xenograft tumor in mice model. Topoisomerase I/II inhibitor 2 has the potential value in researching liver cancer .
    Topoisomerase I/II inhibitor 2
  • HY-162650
    SL44

    		ClpP Cancer
    SL44 is an agonist for human caseinolytic protease P (HsClpP), with an EC50 of 1.30 μM. SL44 inhibits the proliferation of LM3 with an IC50 of 3.1 μM. SL44 induces apoptosis in HCC cells, through the degradation of respiratory chain complex subunits. SL44 exhibits antitumor efficacy in mouse models without obvious toxicity (LD50=400 mg/kg). SL44 exhibits good pharmacokinetic characters in rat models .
    SL44
  • HY-P99291
    Etaracizumab

    LM 609; MEDI 523; Anti-αvβ3 Integrin Recombinant Antibody

    		 Integrin Apoptosis Akt Cancer
    Etaracizumab (LM 609) is an αvβ3 integrin IgG mAb. Etaracizumab is developed to target αvβ3+ cancer cells via NK cell-mediated cytotoxicity. Etaracizumab sterically hinders access of large ligands to the RGD-binding pocket, without obstructing it. Etaracizumab decreases p-Akt in vitro. Etaracizumab can decrease cancer proliferation and invasion. Etaracizumab induces tumor cell apoptosis, and inhibition ofαvβ3-mediated cell adhesion, endothelial cell migration and osteoclast-mediated bone resorption. Etaracizumab can be studied in anti-tumor research against cancers such as ovarian cancer, metastatic melanoma as well as advanced solid tumors. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Etaracizumab
  • HY-164102
    TNF-α-IN-18

    		TNF Receptor NF-κB Inflammation/Immunology
    TNF-α-IN-18 (Compound 61) is an inhibitor for TNF-α (IC50 of 1.8 μM), that inhibits TNF signaling pathway through block of NF-kB migration from cytoplasm to nucleus. TNF-α-IN-18 exhibits slight cytotoxicity to mouse fibroblast LM cell, with a CC50 >50 μM. TNF-α-IN-18 ameliorates the TNF- or Lipopolysaccharide (HY-D1056)-induced sepsis in mouse models. TNF-α-IN-18 protects mice from rheumatoid arthritis .
    TNF-α-IN-18

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: